A mathematical model of the indirect effects of rotavirus vaccination

Epidemiology and Infection

Volumn 138, Issue 6, 2010, Pages 884-897

  Van Effelterre, T ^a   Soriano Gabarro M ^a   Debrus, S ^a   Claire Newbern, E ^a   Gray, J ^b  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Herd protection; Mathematical model; Rotavirus; Vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE SEVERITY; DISEASE TRANSMISSION; GASTROENTERITIS; HUMAN; IMMUNITY; INFANT; MATHEMATICAL MODEL; MORBIDITY; PRESCHOOL CHILD; ROTAVIRUS INFECTION; SCHOOL CHILD; SENSITIVITY ANALYSIS; BIOLOGICAL MODEL; HEALTH CARE QUALITY; HERD IMMUNITY; MASS IMMUNIZATION; TREATMENT OUTCOME; VIROLOGY;

GASTROENTERITIS; HUMANS; IMMUNITY, HERD; MASS VACCINATION; MODELS, BIOLOGICAL; PROGRAM EVALUATION; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; TREATMENT OUTCOME;

EID: 77952468355     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268809991245     Document Type: Article

References (50)

1. Parashar UD, et al. Global illness and deaths caused by rotavirus disease in children. Emerging Infectious Diseases 2003; 9: 565-572.
2. Soriano-Gabarro M, et al. Burden of rotavirus disease in European Union countries. Pediatric Infectious Diseases Journal 2006; 25 (Suppl. 1) : S7-S11.
3. Forster J, et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children aged <5 years. In: Abstract from the 25th Annual Meeting of the European Society for Paediatric Infectious Diseases, Porto, Portugal, 2007.
4. Bishop RF, et al. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. New England Journal of Medicine 1983; 309: 72-76.
5. Velazquez FR, et al. Rotavirus infections in infants as protection against subsequent infections. New England Journal of Medicine 1996; 335: 1022-1028.
6. Vesikari T, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants : randomised, double-blind controlled study. Lancet 2007; 370: 1757-1763.
7. Vesikari T, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine 2006; 354: 23-33. (Pubitemid 43048948)
8. Heymann DL, Aylward RB. Mass vaccination: when and why. Current Topics in Microbiology and Immunology 2006; 304: 1-16.
9. Vesikari T, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidencebased recommendations for rotavirus vaccination in Europe: executive summary. Journal of Pediatric Gastroenterology and Nutrition 2008; 46: 615-618.
10. Anon. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Weekly Epidemiological Record 2009; 84: 220-236.
11. Goossens LM, et al. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008; 26: 1118-1127.
12. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential costeffectiveness of vaccination. Vaccine 2007; 25: 3971-3979. (Pubitemid 46616994)
13. Melliez H, et al. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008; 26: 706-715.
14. Newall AT, et al. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007; 25: 8851-8860.
15. Jit M, et al. The cost-effectiveness of rotavirus vaccination : Comparative analyses for five European countries and transferability in Europe. Vaccine 2009; 27: 6121-6128.
16. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Medical Decision Making 2003; 23: 76-82.
17. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Statistics in Medicine 1999; 18: 3263-3282.
18. Van Damme P, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. Journal of Infectious Diseases 2007; 195 (Suppl. 1) : S4-S16.
19. Anderson RM, May RM. Infectious Diseases of Humans. Dynamics and Control. Oxford University Press, 1991.
20. Fischer TK, et al. Protective immunity after natural rotavirus infection : a community cohort study of newborn children in Guinea-Bissau, west Africa. Journal of Infectious Diseases 2002; 186: 593-597.
21. Moulton LH, et al. The protective effectiveness of natural rotavirus infection in an American Indian population. Journal of Infectious Diseases 1998; 178: 1562-1566.
22. Hartter HK, et al. Placental transfer and decay of maternally acquired antimeasles antibodies in Nigerian children. Pediatric Infectious Diseases Journal 2000; 19: 635-641.
23. Lee MS, et al. Half-life of human parainfluenza virus type 3 (hPIV3) maternal antibody and cumulative proportion of hPIV3 infection in young infants. Journal of Infectious Diseases 2001; 183: 1281-1284.
24. McLean B, Holmes IH. Transfer of antirotaviral antibodies from mothers to their infants. Journal of Clinical Microbiology 1980; 12: 320-325.
25. Watanaveeradej V, et al. Transplacentally transferred maternal-infant antibodies to dengue virus. American Journal of Tropical Medicine and Hygiene 2003; 69: 123-128.
26. Williams CJ, Lobanov A, Pebody RG. Estimated mortality and hospital admission due to rotavirus infection in the WHO European region. Epidemiology and Infection 2009; 137: 607-616.
27. Robert Koch Institute. Survstat (http://www3.rki.de/ SurvStat).
28. Bishop R. Natural history of human rotavirus infections. In: Kapikian AZ, ed. Viral Infections of the Gastrointestinal Tract, 2nd edn. New York: Marcel Dekker, 1994, pp. 131-167.
29. Desselberger U, Gray J. Viral Gastroenteritis. Amsterdam: Elsevier Science, 2003.
30. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases, 10th edn. Washington, DC: Public Health Foundation, 2007.
31. Hethcote HW. Modeling heterogeneous mixing in infectious disease dynamics. In: Isham V, Medley G, eds. Models for Infectious Human Diseases : Their Structure and Relation to Data. Cambridge: Cambridge University Press, 1996, pp. 215-238.
32. Mossong J, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Medicine 2008; 5: e74.
33. U.S. Census Bureau. International Data Base (http:// www.census.gov/ipc/ www/idb/informationGateway. php).
34. Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. American Journal of Epidemiology 2005; 162: 89-100.
35. Carraro E, et al. Rotavirus infection in children and adult patients attending in a tertiary Hospital of Sao Paulo, Brazil. Brazilian Journal of Infectious Diseases 2008; 12: 44-46.
36. Hrdy DB. Epidemiology of rotaviral infection in adults. Review of Infectious Diseases 1987; 9: 461-469.
37. Iijima Y, et al. An outbreak of rotavirus infection among adults in an institution for rehabilitation : longterm residence in a closed community as a risk factor for rotavirus illness. Scandinavian Journal of Infectious Diseases 2006; 38: 490-496.
38. Lexau CA, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. Journal of the American Medical Association 2005; 294: 2043-2051.
39. Van Effelterre TP, Standaert BA. Potential impact of a high vaccine coverage against rotavirus diarrhea in Belgium. In: Abstract from the Vaccine Global Congress. Amsterdam, Netherlands, 2007.
40. Electronic Medicines Compendium (eMC). (http://emc. medicines.org.uk/ document.aspx?documentId=17840).
41. Forster J, et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics 2009; 123: e393-400.
42. De Vos B, et al. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials. Pediatric Infectious Diseases Journal 2009; 28: 261-266.
43. Iturriza-Gómara M, et al. Rotavirus surveillance in Europe 2005-2008: web-enabled reporting and real-time analysis of genotyping and epidemiological data. Journal of Infectious Diseases (in press).
44. Jose MV, Bobadilla JR. Epidemiological model of diarrhoeal diseases and its application in prevention and control. Vaccine 1994; 12: 109-116.
45. Shim E, et al. An age-structured epidemic model of rotavirus with vaccination. Journal of Mathematical Biology 2006; 53: 719-746.
46. Shim E, Galvani AP. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 2009; 27: 4025-4030.
47. Pitzer VE, et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 2009; 325: 290-294.
48. Centers for Disease Control and Prevention. Delayed onset and diminished magnitude of rotavirus activity - United States, November 2007-May 2008. Morbidity and Mortality Weekly Report 2008; 57: 697-700.
49. Payne DC, et al. Decline in rotavirus hospitalizations in 3 US counties after introduction of rotavirus vaccine In: Abstract from the Pediatric Academic Societies Meeting, Baltimore, MD, 2009.
50. Safadi M, et al. Hospital-based surveillance to evaluate the impact of rotavirus vaccination in Brazil. In: Abstract from the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases,. Brussels, Belgium, 2009.